Synthesis and structure-activity study of protease inhibitors. IV. Amidinonaphthols and related acyl derivatives.

Suppr

超能文献

作者信息

Aoyama T, Okutome T, Nakayama T, Yaegashi T, Matsui R, Nunomura S, Kurumi M, Sakurai Y, Fujii S

出版信息

Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1458-71. doi: 10.1248/cpb.33.1458.

DOI:10.1248/cpb.33.1458

PMID:4042222

Abstract

摘要

相似文献

Synthesis and structure-activity study of protease inhibitors. IV. Amidinonaphthols and related acyl derivatives.

Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1458-71. doi: 10.1248/cpb.33.1458.

Synthesis and structure-activity study of protease inhibitors. III. Amidinophenols and their benzoyl esters.

Chem Pharm Bull (Tokyo). 1984 Nov;32(11):4466-77. doi: 10.1248/cpb.32.4466.

Irreversible enzyme inhibitors. CLXV. Proteolytic enzymes. XV. Inhibition of guinea pig complement by derivatives of m-phenoxypropoxybenzamidine.

J Med Chem. 1969 Nov;12(6):1053-6. doi: 10.1021/jm00306a020.

[Synthetic inhibitors of serine proteinases. 35. Inhibition action of amidino- and guanidinophenyl derivatives against hemolysis initiated by complement activation].

Pharmazie. 1989 Feb;44(2):141-4.

Aromatic tetra-amidines: synthesis of halo-derivatives and their antiproteolytic activity.

Farmaco Sci. 1984 Nov;39(11):901-9.

Inhibition of the haemolytic complement activity by derivatives of benzamidine.

Biochem Pharmacol. 1977 Feb 15;26(4):325-9. doi: 10.1016/0006-2952(77)90185-x.

Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors.

Bioorg Med Chem Lett. 2005 May 2;15(9):2249-52. doi: 10.1016/j.bmcl.2005.03.019.

Irreversible enzyme inhibitors. CLXIV. Proteolytic enzymes. XIV. Inhibition of guinea pig complement by meta-substituted benzamidines.

J Med Chem. 1969 Nov;12(6):1049-52. doi: 10.1021/jm00306a019.

Synthesis and structure-activity study of protease inhibitors. I. (Guanidinophenyl)propionate and guanidinocinnamate derivatives.

Chem Pharm Bull (Tokyo). 1984 May;32(5):1854-65. doi: 10.1248/cpb.32.1854.

Synthesis and structure-activity study of protease inhibitors. V. Chemical modification of 6-amidino-2-naphthyl 4-guanidinobenzoate.

Chem Pharm Bull (Tokyo). 1993 Jan;41(1):117-25. doi: 10.1248/cpb.41.117.

引用本文的文献

Predicting the systemic exposure and lung concentration of nafamostat using physiologically-based pharmacokinetic modeling.

Transl Clin Pharmacol. 2022 Dec;30(4):201-211. doi: 10.12793/tcp.2022.30.e20. Epub 2022 Dec 21.

Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19.

Transl Clin Pharmacol. 2022 Mar;30(1):24-36. doi: 10.12793/tcp.2022.30.e4. Epub 2022 Mar 9.

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis.

Molecules. 2022 Mar 14;27(6):1881. doi: 10.3390/molecules27061881.

Synthesis and Cytotoxicity of N-Substituted Dibenzo[a,j]xanthene-3,11-dicarboxamide Derivatives.

Molecules. 2017 Mar 23;22(4):517. doi: 10.3390/molecules22040517.

Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct.

Br J Pharmacol. 1994 Jan;111(1):173-8. doi: 10.1111/j.1476-5381.1994.tb14040.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验